ABSCINT NV

ABSCINT | Molecular Imaging Company

Patients can live healthier and longer lives when disease progression is prevented or delayed. This can only happen if patients get a timely diagnosis, which is then followed by appropriate clinical management. With the apparition of more complex and expensive therapies, the need for better diagnostic tools becomes essential. Disease specific aberrant cells, , can be detected via radiolabelled molecules by means of whole body molecular imaging, a method where the whole body is scanned to highlight and locate lesions where the aberrant cells resides. ABSCINT’s business model is to develop and sell single-domain antibody tracers directly to the hospitals and physicians in the field of oncology, cardiology and immunology. The tracers will be available in kit-form for an easy on-site radiolabelling and patient administration. Furthermore, business development deals with therapeutic companies will be established to use ABSCINT’s kits in clinical trials in order to monitor the efficacy of their treatment.

617K€ was already raised from investors, a 1.77 Mio € grant was obtained from the Walloon region (Belgium) with a second tranche of 1.3 Mio € which will be obtained after a go/no go decision (08/2022). | Next step: GMP production of material and pivotal clinical trials  | € 6 Mio € sought